Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142278 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142325 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142242 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL7589367 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142505 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL10464715 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL19992803 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142869 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL21126454 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL15006368 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| EP-3538575-B1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | BRIDGESTONE CORP (JP) | 2024-03-13 | — | — | EP | disclosed |
| US-11884767-B2 | High cis-1,4 block copolymers of polybutadiene and polyisoprene | BRIDGESTONE CORPORATION (JP) | 2024-01-30 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220119573-A1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | BRIDGESTONE CORPORATION (JP) | 2022-04-21 | — | — | US | disclosed |
| US-11230622-B2 | High cis-1,4 block copolymers of polybutadiene and polyisoprene | BRIDGESTONE CORPORATION (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210388196-A1 | GENE DELIVERY CARRIER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| US-11041069-B2 | Gene delivery carrier | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3538575-A1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | Bridgestone Corporation (JP) | 2019-09-18 | — | — | EP | disclosed |
| CN-110139882-A | High cis-1, 4 block copolymers of polybutadiene and polyisoprene | 株式会社普利司通 | 2019-08-16 | — | — | CN | disclosed |
| US-20190194444-A1 | GENE DELIVERY CARRIER | POLITECNICO DI MILANO (IT) | 2019-06-27 | — | — | US | disclosed |
| WO-2018089635-A1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | BRIDGESTONE CORPORATION (JP) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194444-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | DNM1 4619/4885TSHR 3794/4885THRB 2797/4885 |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | DNM1 307/4885TSHR 2262/4885THRB 2609/4885 |
| US-11041069-B2 | Gene delivery carrier | PAICS, PBDC1, BCAT1 | DNM1 4619/4885TSHR 3794/4885THRB 2797/4885 |
| US-20210388196-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | DNM1 4619/4885TSHR 3794/4885THRB 2797/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | DNM1 1488/4885TSHR 2016/4885THRB 1435/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DNM1 4044/4885TSHR 3319/4885THRB 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.